


Current Lung-MAP Schema

- Actively Accruing
- In Development



¹ Acquired Resistance is defined as progression at least (\geq) 84 days from initiation of the most recent line of anti-PD-1/PD-L1 and best response of stable disease, partial response, or complete response.

² Approved by the Lung-MAP Drug Selection Committee

³ Includes both Acquired and Primary Resistant Groups